Literature DB >> 23233254

Allele-specific siRNA silencing for the common keratin 12 founder mutation in Meesmann epithelial corneal dystrophy.

Edwin H A Allen1,2, Sarah D Atkinson1,2, Haihui Liao2, Jonathan E Moore1, Deena M Leslie Pedrioli2, Frances J D Smith2, W H Irwin McLean2, C B Tara Moore1,2.   

Abstract

PURPOSE: To identify an allele-specific short interfering RNA (siRNA), against the common KRT12 mutation Arg135Thr in Meesmann epithelial corneal dystrophy (MECD) as a personalized approach to treatment.
METHODS: siRNAs against the K12 Arg135Thr mutation were evaluated using a dual luciferase reporter gene assay and the most potent and specific siRNAs were further screened by Western blot. Off-target effects on related keratins were assessed and immunological stimulation of TLR3 was evaluated by RT-PCR. A modified 5' rapid amplification of cDNA ends method was used to confirm siRNA-mediated mutant knockdown. Allele discrimination was confirmed by quantitative infrared immunoblotting.
RESULTS: The lead siRNA, with an IC(50) of thirty picomolar, showed no keratin off-target effects or activation of TLR3 in the concentration ranges tested. We confirmed siRNA-mediated knockdown by the presence of K12 mRNA fragments cleaved at the predicted site. A dual tag infrared immunoblot showed knockdown to be allele-specific, with 70% to 80% silencing of the mutant protein.
CONCLUSIONS: A potent allele-specific siRNA against the K12 Arg135Thr mutation was identified. In combination with efficient eyedrop formulation delivery, this would represent a personalized medicine approach, aimed at preventing the pathology associated with MECD and other ocular surface pathologies with dominant-negative or gain-of-function pathomechanisms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23233254      PMCID: PMC3869971          DOI: 10.1167/iovs.12-10528

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  42 in total

Review 1.  Challenges in developing therapies for rare diseases including pachyonychia congenita.

Authors:  Roger L Kaspar
Journal:  J Investig Dermatol Symp Proc       Date:  2005-10

Review 2.  The business of RNAi therapeutics.

Authors:  Dirk Haussecker
Journal:  Hum Gene Ther       Date:  2008-05       Impact factor: 5.695

3.  Characterisation and functional features of a spontaneously immortalised human corneal epithelial cell line with progenitor-like characteristics.

Authors:  Maria Notara; Julie T Daniels
Journal:  Brain Res Bull       Date:  2009-08-21       Impact factor: 4.077

Review 4.  Gene delivery to cornea.

Authors:  Jinsong Hao; S Kevin Li; Winston W Y Kao; Chia-Yang Liu
Journal:  Brain Res Bull       Date:  2009-06-26       Impact factor: 4.077

5.  Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3.

Authors:  Mark E Kleinman; Hiroki Kaneko; Won Gil Cho; Sami Dridi; Benjamin J Fowler; Alexander D Blandford; Romulo J C Albuquerque; Yoshio Hirano; Hiroko Terasaki; Mineo Kondo; Takashi Fujita; Balamurali K Ambati; Valeria Tarallo; Bradley D Gelfand; Sasha Bogdanovich; Judit Z Baffi; Jayakrishna Ambati
Journal:  Mol Ther       Date:  2011-10-11       Impact factor: 11.454

6.  Triggering of TLR3 by polyI:C in human corneal epithelial cells to induce inflammatory cytokines.

Authors:  Mayumi Ueta; Junji Hamuro; Hiroshi Kiyono; Shigeru Kinoshita
Journal:  Biochem Biophys Res Commun       Date:  2005-05-27       Impact factor: 3.575

7.  BIGH3 mutation spectrum in corneal dystrophies.

Authors:  Francis L Munier; Beatrice E Frueh; Philippe Othenin-Girard; Sylvie Uffer; Pascal Cousin; Ming X Wang; Elise Héon; Graeme C M Black; Maria A Blasi; Emilio Balestrazzi; Birgit Lorenz; Rafael Escoto; Rafael Barraquer; Maria Hoeltzenbein; Balder Gloor; Maurizio Fossarello; Arun D Singh; Yvan Arsenijevic; Léonidas Zografos; Daniel F Schorderet
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-04       Impact factor: 4.799

8.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

9.  First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.

Authors:  Sancy A Leachman; Robyn P Hickerson; Mary E Schwartz; Emily E Bullough; Stephen L Hutcherson; Kenneth M Boucher; C David Hansen; Mark J Eliason; G Susan Srivatsa; Douglas J Kornbrust; Frances Jd Smith; Wh Irwin McLean; Leonard M Milstone; Roger L Kaspar
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

10.  Single-nucleotide-specific siRNA targeting in a dominant-negative skin model.

Authors:  Robyn P Hickerson; Frances J D Smith; Robert E Reeves; Christopher H Contag; Devin Leake; Sancy A Leachman; Leonard M Milstone; W H Irwin McLean; Roger L Kaspar
Journal:  J Invest Dermatol       Date:  2007-10-11       Impact factor: 8.551

View more
  10 in total

1.  PKC412 normalizes mutation-related keratin filament disruption and hepatic injury in mice by promoting keratin-myosin binding.

Authors:  Raymond Kwan; Lu Chen; Koksun Looi; Guo-Zhong Tao; Sujith V Weerasinghe; Natasha T Snider; Mary Anne Conti; Robert S Adelstein; Qing Xie; M Bishr Omary
Journal:  Hepatology       Date:  2015-08-25       Impact factor: 17.425

2.  Non-Invasive Intravital Imaging of siRNA-Mediated Mutant Keratin Gene Repression in Skin.

Authors:  Robyn P Hickerson; Tycho J Speaker; Maria Fernanda Lara; Emilio González-González; Manuel A Flores; Christopher H Contag; Roger L Kaspar
Journal:  Mol Imaging Biol       Date:  2016-02       Impact factor: 3.488

3.  High-Throughput Screening for Drugs that Modulate Intermediate Filament Proteins.

Authors:  Jingyuan Sun; Vincent E Groppi; Honglian Gui; Lu Chen; Qing Xie; Li Liu; M Bishr Omary
Journal:  Methods Enzymol       Date:  2015-11-19       Impact factor: 1.600

4.  Keratin 12 missense mutation induces the unfolded protein response and apoptosis in Meesmann epithelial corneal dystrophy.

Authors:  Edwin H A Allen; David G Courtney; Sarah D Atkinson; Johnny E Moore; Laura Mairs; Ebbe Toftgaard Poulsen; Davide Schiroli; Eleonora Maurizi; Christian Cole; Robyn P Hickerson; John James; Helen Murgatroyd; Frances J D Smith; Carrie MacEwen; Jan J Enghild; M Andrew Nesbit; Deena M Leslie Pedrioli; W H Irwin McLean; C B Tara Moore
Journal:  Hum Mol Genet       Date:  2016-01-11       Impact factor: 6.150

5.  Identification of presumed pathogenic KRT3 and KRT12 gene mutations associated with Meesmann corneal dystrophy.

Authors:  Judy L Chen; Benjamin R Lin; Katherine M Gee; Jessica A Gee; Duk-Won D Chung; Ricardo F Frausto; Sophie X Deng; Anthony J Aldave
Journal:  Mol Vis       Date:  2015-12-31       Impact factor: 2.367

6.  Towards personalised allele-specific CRISPR gene editing to treat autosomal dominant disorders.

Authors:  Kathleen A Christie; David G Courtney; Larry A DeDionisio; Connie Chao Shern; Shyamasree De Majumdar; Laura C Mairs; M Andrew Nesbit; C B Tara Moore
Journal:  Sci Rep       Date:  2017-11-23       Impact factor: 4.379

7.  ASPsiRNA: A Resource of ASP-siRNAs Having Therapeutic Potential for Human Genetic Disorders and Algorithm for Prediction of Their Inhibitory Efficacy.

Authors:  Isha Monga; Abid Qureshi; Nishant Thakur; Amit Kumar Gupta; Manoj Kumar
Journal:  G3 (Bethesda)       Date:  2017-09-07       Impact factor: 3.154

8.  Development of a Corneal Bioluminescence Mouse for Real-Time In Vivo Evaluation of Gene Therapies.

Authors:  Dun Jack Fu; Edwin H A Allen; Robyn P Hickerson; Deena M Leslie Pedrioli; W H Irwin McLean
Journal:  Transl Vis Sci Technol       Date:  2020-12-29       Impact factor: 3.283

9.  Allele-specific silencing of EEC p63 mutant R304W restores p63 transcriptional activity.

Authors:  F Novelli; A M Lena; E Panatta; W Nasser; R Shalom-Feuerstein; E Candi; G Melino
Journal:  Cell Death Dis       Date:  2016-05-19       Impact factor: 8.469

10.  CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting.

Authors:  D G Courtney; J E Moore; S D Atkinson; E Maurizi; E H A Allen; D M L Pedrioli; W H I McLean; M A Nesbit; C B T Moore
Journal:  Gene Ther       Date:  2015-08-20       Impact factor: 5.250

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.